Literature DB >> 25931655

Physical therapy for an adult with chronic stroke after botulinum toxin injection for spasticity: a case report.

Shannon Gallagher1, Chetan P Phadke2, Farooq Ismail3, Chris Boulias3.   

Abstract

PURPOSE: In this case report, we describe the type and duration of a physical therapy and botulinum toxin type A (BoNTA) intervention directed at lower limb spasticity and the gait and balance improvement in a patient post-stroke. Treatment of focal spasticity with BoNTA intramuscular injections combined with physical therapy is recommended by rehabilitation experts. However, the optimal type and duration of physical therapy intervention to optimize any functional gains that follow chemodenervation induced by BoNTA has not been established.
METHOD: One individual with chronic stroke who received BoNTA injections for upper and lower extremity spasticity was included. Physical therapy intervention consisted of 45- to 60-min sessions twice weekly for 12 weeks, based on the Bobath-neurodevelopmental therapy approach, and an activity-based home program.
RESULTS: After BoNTA injections and physical therapy, the patient made clinically significant improvements in balance and gait speed and became more independent with his ambulation.
CONCLUSIONS: This case report demonstrates that physical therapy after BoNTA injections can result in significant functional improvements for individuals with spasticity after chronic stroke that may not be possible with BoNTA injections alone.

Entities:  

Keywords:  botulinum toxins; muscle spasticity; stroke

Year:  2015        PMID: 25931655      PMCID: PMC4403330          DOI: 10.3138/ptc.2013-73

Source DB:  PubMed          Journal:  Physiother Can        ISSN: 0300-0508            Impact factor:   1.037


  9 in total

1.  Augmenting occupational therapy treatment of upper-extremity spasticity with botulinum toxin A: a case report of progress at discharge and 2 years later.

Authors:  Susan P Denham
Journal:  Am J Occup Ther       Date:  2008 Jul-Aug

2.  Botulinum toxin: historical perspective and potential new indications.

Authors:  J Jankovic; M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

3.  Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability.

Authors:  Steven L Wolf; S Byron Milton; Aimee Reiss; Kirk A Easley; Neeta V Shenvi; Patricia C Clark
Journal:  Arch Phys Med Rehabil       Date:  2011-12-27       Impact factor: 3.966

4.  Minimal detectable changes of the Berg Balance Scale, Fugl-Meyer Assessment Scale, Timed "Up & Go" Test, gait speeds, and 2-minute walk test in individuals with chronic stroke with different degrees of ankle plantarflexor tone.

Authors:  Vimonwan Hiengkaew; Khanitha Jitaree; Pakaratee Chaiyawat
Journal:  Arch Phys Med Rehabil       Date:  2012-04-12       Impact factor: 3.966

5.  Meaningful gait speed improvement during the first 60 days poststroke: minimal clinically important difference.

Authors:  Julie K Tilson; Katherine J Sullivan; Steven Y Cen; Dorian K Rose; Cherisha H Koradia; Stanley P Azen; Pamela W Duncan
Journal:  Phys Ther       Date:  2009-12-18

Review 6.  Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity.

Authors:  Marina Demetrios; Fary Khan; Lynne Turner-Stokes; Caroline Brand; Shane McSweeney
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

7.  Effect of continued stretching of the affected arm in patients with cerebrovascular diseases by examining H-reflex characteristics.

Authors:  T Suzuki; E Saitoh; M Tani; R Nabeta; S Daikuya; H Hirose; I Wakayama; T Fujiwara
Journal:  Electromyogr Clin Neurophysiol       Date:  2003 Jan-Feb

8.  How much change is true change? The minimum detectable change of the Berg Balance Scale in elderly people.

Authors:  Declan Donoghue; Emma K Stokes
Journal:  J Rehabil Med       Date:  2009-04       Impact factor: 2.912

9.  European consensus table on the use of botulinum toxin type A in adult spasticity.

Authors:  Jörg Wissel; Anthony B Ward; Per Erztgaard; Djamel Bensmail; Martin J Hecht; Thierry M Lejeune; Peter Schnider; Maria C Altavista; Stefano Cavazza; Thierry Deltombe; Esther Duarte; Alexander C H Geurts; Jean-Michel Gracies; Naseer H J Haboubi; Francisco J Juan; Helge Kasch; Christian Kätterer; Yeşim Kirazli; Paolo Manganotti; Yeşim Parman; Tatjana Paternostro-Sluga; Konstantina Petropoulou; Robert Prempeh; Marc Rousseaux; Jaroslaw Slawek; Niko Tieranta
Journal:  J Rehabil Med       Date:  2009-01       Impact factor: 2.912

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.